Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Nutricel Additive System - CP2D

×

Overview

What is Nutricel Additive System - CP2D?

CP2D/AS-3 Blood Collection and Sampling System with Nutricel Additive System

Instruction for Use for Systems Containing a Y Sampling Site (YSS) or Sample Diversion Pouch (with or without a pre-attached SampLok Vacuum Tube Holder).

Refer to unit foil package label for specific product description being used.

Sterile, nonpyrogenic fluid path. Sterilized by steam.

Rx only.

This product is free of natural rubber latex.



What does Nutricel Additive System - CP2D look like?



What are the available doses of Nutricel Additive System - CP2D?

Sorry No records found.

What should I talk to my health care provider before I take Nutricel Additive System - CP2D?

Sorry No records found

How should I use Nutricel Additive System - CP2D?

For collection of blood and preparation of red blood cells, plasma and platelets.


What interacts with Nutricel Additive System - CP2D?

Sorry No Records found


What are the warnings of Nutricel Additive System - CP2D?

One of 47 Parkinson’s disease patient volunteers enrolled in phase 1 studies had documented hypotension following a 2-mg dose on 2 occasions. In double-blind, placebo-controlled, early-therapy studies in patients with Parkinson’s disease who were not treated with L-dopa, 5.2% (8 of 157) of patients treated with Ropinirole Hydrochloride Tablets reported hallucinations, compared to 1.4% of patients on placebo (2 of 147). Among those patients receiving both Ropinirole Hydrochloride Tablets and L-dopa in advanced Parkinson’s disease (with L-dopa) studies, 10.1% (21 of 208) were reported to experience hallucinations, compared to 4.2% (5 of 120) of patients treated with placebo and L-dopa. Hallucinations were of sufficient severity to cause discontinuation of treatment in 1.3% of the early Parkinson’s disease (without L-dopa) patients and 1.9% of the advanced Parkinson’s disease (with L-dopa) patients, compared to 0% and 1.7% of placebo patients, respectively.In patients with RLS, hallucinations were reported by 0% of patients treated with Ropinirole Hydrochloride Tablets (0 of 496) compared with 0.2% of patients who received placebo (1 of 500) in the 12-week placebo-controlled trials; in premarketing long-term open-label studies, 0.5% of patients reported hallucinations during therapy with Ropinirole Hydrochloride Tablets (2 of 390) but did not discontinue treatment and symptoms resolved.


What are the precautions of Nutricel Additive System - CP2D?

Sorry No Records found


What are the side effects of Nutricel Additive System - CP2D?

Sorry No records found


What should I look out for while using Nutricel Additive System - CP2D?

Failure to achieve and maintain a closed system during processing would result in a product that must be transfused within 24 hours.


What might happen if I take too much Nutricel Additive System - CP2D?

Sorry No Records found


How should I store and handle Nutricel Additive System - CP2D?

Dispense in a well-closed container as defined in the USP.Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].ArrayDispense in a well-closed container as defined in the USP.Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].ArrayDispense in a well-closed container as defined in the USP.Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].ArrayEach shipping case contains 8 foil envelopes. Within each foil envelope resides 3 clear pouches containing an individual collection system. Each collection system consists of CP2D/AS-3 500 ml, Double Blood Bag Collection System with Nutricel Additive Solution and Sample Diversion Pouch.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Non-Clinical Toxicology
Failure to achieve and maintain a closed system during processing would result in a product that must be transfused within 24 hours.

In vitro

Use aseptic technique. Use only if solutions are clear. If preparing a platelet concentrate, the platelet-rich plasma should be separated from the red blood cells within 8 hours after blood collection. If preparing fresh frozen plasma, separate from the red blood cells and place in the freezer at -18 °C or colder within 8 hours after collection.

During processing, always observe the following precautions:

1. Sealing should be done in a manner that avoids fluid splatter.

2. Always dispose of blood-contaminated products in a manner consistent with established BIOHAZARD safety procedures.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).